| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $9,752,105 | 25 | 100 |
| Ware J. Anthony | director | 0 | $0 | 1 | $193,343 | $-193,343 |
| RENTON HOLLINGS | director | 0 | $0 | 1 | $249,372 | $-249,372 |
| Lizzul Paul F. | Chief Medical Officer | 0 | $0 | 4 | $521,526 | $-521,526 |
| Marquet Magda | director | 0 | $0 | 1 | $530,531 | $-530,531 |
| Schmid John P. | director | 0 | $0 | 1 | $1.16M | $-1.16M |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 0 | $0 | 5 | $1.55M | $-1.55M |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 0 | $0 | 8 | $2.74M | $-2.74M |
| Faga Daniel | President, CEO | 0 | $0 | 4 | $2.81M | $-2.81M |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid …
Over the last 12 months, insiders at AnaptysBio, Inc. have bought $0 and sold $9.75M worth of AnaptysBio, Inc. stock.
On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $8.52M and sold $6.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,646 shares for transaction amount of $86,070 was made by EcoR1 Capital, LLC () on 2025‑01‑02.
| 2026-10-01 | Sale | RENTON HOLLINGS | director | 5,000 0.0173% | $49.87 | $249,372 | -1.42% | |
| 2026-03-30 | Sale | Schmid John P. | director | 20,645 0.0728% | $56.11 | $1.16M | +49.08% | |
| 2026-03-27 | Sale | Faga Daniel | President, CEO | 17,679 0.066% | $61.61 | $1.09M | +43.79% | |
| 2026-02-11 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 10,000 0.0353% | $54.00 | $540,000 | +45.40% | |
| 2026-01-15 | Sale | Marquet Magda | director | 11,000 0.0414% | $48.23 | $530,531 | +67.38% | |
| 2026-01-08 | Sale | Faga Daniel | President, CEO | 14,281 0.0526% | $44.71 | $638,504 | +75.74% | |
| 2026-01-08 | Sale | Lizzul Paul F. | Chief Medical Officer | 3,650 0.0135% | $44.71 | $163,192 | +75.74% | |
| 2026-01-08 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 2,515 0.0093% | $44.71 | $112,446 | +75.74% | |
| 2026-01-08 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 2,210 0.0081% | $44.71 | $98,809 | +75.74% | |
| 2026-01-07 | Sale | Faga Daniel | President, CEO | 9,202 0.0334% | $45.11 | $415,102 | +70.11% | |
| 2026-01-07 | Sale | Lizzul Paul F. | Chief Medical Officer | 2,235 0.0081% | $45.11 | $100,821 | +70.11% | |
| 2026-01-07 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 1,908 0.0069% | $45.11 | $86,070 | +70.11% | |
| 2026-01-07 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 9,639 0.0353% | $45.56 | $439,200 | +70.11% | |
| 2026-01-05 | Sale | Faga Daniel | President, CEO | 15,309 0.0554% | $43.26 | $662,267 | +77.99% | |
| 2026-01-05 | Sale | Lizzul Paul F. | Chief Medical Officer | 4,219 0.0153% | $43.26 | $182,514 | +77.99% | |
| 2026-01-05 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 3,363 0.0122% | $43.26 | $145,483 | +77.99% | |
| 2026-01-05 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 2,983 0.0108% | $43.26 | $129,045 | +77.99% | |
| 2025-12-23 | Sale | Ware J. Anthony | director | 3,900 0.0139% | $49.58 | $193,343 | +52.50% | |
| 2025-12-22 | Sale | Lizzul Paul F. | Chief Medical Officer | 1,500 0.0054% | $50.00 | $75,000 | +51.42% | |
| 2025-12-22 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 10,000 0.0359% | $50.00 | $500,000 | +51.42% |
| Ware J. Anthony | director | 9630 0.0322% | $459,639.90 | 1 | 1 | +16.45% |
| EcoR1 Capital, LLC | 7880094 26.3591% | $376.12M | 13 | 0 | +22.23% | |
| NODELMAN OLEG | 7521024 25.158% | $358.98M | 1 | 1 | +12.83% | |
| Novo Holdings A/S | 10 percent owner | 1936604 6.478% | $92.43M | 1 | 8 | +59.03% |
| Topper James N | 1045031 3.4956% | $49.88M | 1 | 0 | +59.03% | |
| Frazier Healthcare V, LP | 10 percent owner | 311291 1.0413% | $14.86M | 1 | 0 | +59.03% |
| Frazier Healthcare VII, L.P. | 10 percent owner | 311291 1.0413% | $14.86M | 1 | 0 | +59.03% |
| Lydon Nicholas | director | 271106 0.9069% | $12.94M | 1 | 1 | +59.03% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$831,902,292 | 108 | 9.34% | $1.2B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B |
| Increased Positions | 87 | +41.43% | 3M | +9.66% |
| Decreased Positions | 92 | -43.81% | 6M | -18.81% |
| New Positions | 34 | New | 1M | New |
| Sold Out Positions | 26 | Sold Out | 2M | Sold Out |
| Total Postitions | 205 | -2.38% | 29M | -9.15% |
| Ecor1 Capital, Llc | $354,210.00 | 28.14% | 7.88M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $101,835.00 | 8.09% | 2.27M | -209,346 | -8.46% | 2025-09-30 |
| Blackrock, Inc. | $77,418.00 | 6.15% | 1.72M | -64,610 | -3.62% | 2025-09-30 |
| Morgan Stanley | $69,954.00 | 5.56% | 1.56M | -313,582 | -16.77% | 2025-09-30 |
| Millennium Management Llc | $68,289.00 | 5.43% | 1.52M | +1M | +646.4% | 2025-09-30 |
| Vanguard Group Inc | $66,391.00 | 5.28% | 1.48M | -60,561 | -3.94% | 2025-09-30 |
| Tang Capital Management Llc | $59,947.00 | 4.76% | 1.33M | +2,760 | +0.21% | 2025-09-30 |
| First Light Asset Management, Llc | $44,508.00 | 3.54% | 990,161 | -3M | -72.03% | 2025-09-30 |
| State Street Corp | $39,261.00 | 3.12% | 873,432 | +52,401 | +6.38% | 2025-09-30 |
| Assenagon Asset Management S.A. | $37,755.00 | 3% | 839,934 | +822,975 | +4,852.73% | 2025-09-30 |